Coenzyme Q10 Supplementation May Be Correlated With Resolution of New Daily Persistent Headache

Area of Science:

• Neurology
• Pediatric Headache Disorders

Background:

• New daily persistent headache (NDPH) is a chronic, treatment-resistant primary headache disorder.
• Limited guidance exists for effective NDPH management, impacting quality of life.
• Few studies have identified targeted therapies for NDPH symptom resolution.

Purpose of the Study:

• To describe outcomes in pediatric patients diagnosed with NDPH.
• To assess associations between specific interventions and headache resolution in pediatric NDPH.
• To identify potential therapeutic targets for NDPH.

Main Methods:

• Retrospective review of a patient registry at Children's National Hospital.
• Inclusion of pediatric patients diagnosed with NDPH.
• Analysis of demographic characteristics, clinical features, prior treatments, and resolution rates.
• Statistical comparisons between resolved and non-resolved headache groups.

Main Results:

• 182 pediatric patients were included (mean age 15.5 years; 78% female).
• Headache resolution occurred in 47 patients (25.8%).
• Coenzyme Q10 (CoQ10) supplementation was significantly associated with headache resolution (17% vs 4%, P=.010).
• Magnesium, topiramate, and onabotulinum toxin A injections showed trends toward significance.
• Regular exercise was associated with a trend toward higher resolution rates (P=.058).

Conclusions:

• Coenzyme Q10 (CoQ10) supplementation may play a role in pediatric NDPH resolution.
• Exercise, magnesium, topiramate, and onabotulinum toxin A injections may offer potential benefits.
• Further prospective studies and randomized controlled trials are needed to establish causality and optimize NDPH treatment strategies.